company background image

Saniona OM:SANION Stock Report

Last Price


Market Cap







27 Jun, 2022


Company Financials
SANION fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

SANION Stock Overview

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark.

Saniona Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Saniona
Historical stock prices
Current Share Pricekr3.10
52 Week Highkr20.30
52 Week Lowkr1.57
1 Month Change10.71%
3 Month Change3.33%
1 Year Change-81.50%
3 Year Change-83.49%
5 Year Change-93.47%
Change since IPO-39.81%

Recent News & Updates

Shareholder Returns

SANIONSE BiotechsSE Market

Return vs Industry: SANION underperformed the Swedish Biotechs industry which returned -20.4% over the past year.

Return vs Market: SANION underperformed the Swedish Market which returned -23.6% over the past year.

Price Volatility

Is SANION's price volatile compared to industry and market?
SANION volatility
SANION Average Weekly Movement27.0%
Biotechs Industry Average Movement8.1%
Market Average Movement7.4%
10% most volatile stocks in SE Market12.2%
10% least volatile stocks in SE Market4.7%

Stable Share Price: SANION is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 27% a week.

Volatility Over Time: SANION's weekly volatility has increased from 15% to 27% over the past year.

About the Company

201156Thomas Feldthus

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders.

Saniona Fundamentals Summary

How do Saniona's earnings and revenue compare to its market cap?
SANION fundamental statistics
Market Capkr193.40m
Earnings (TTM)-kr460.87m
Revenue (TTM)kr13.67m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SANION income statement (TTM)
Cost of Revenuekr5.41m
Gross Profitkr8.25m
Other Expenseskr469.12m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)-7.39
Gross Margin60.40%
Net Profit Margin-3,372.64%
Debt/Equity Ratio50.4%

How did SANION perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is SANION undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SANION?

Other financial metrics that can be useful for relative valuation.

SANION key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA-0.03x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SANION's PS Ratio compare to its peers?

SANION PS Ratio vs Peers
The above table shows the PS ratio for SANION vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average607.5x
ABLI Abliva
DEX Dextech Medical
VIVE Vivesto
SANION Saniona

Price-To-Sales vs Peers: SANION is good value based on its Price-To-Sales Ratio (14.2x) compared to the peer average (608.8x).

Price to Earnings Ratio vs Industry

How does SANION's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Sales vs Industry: SANION is good value based on its Price-To-Sales Ratio (14.2x) compared to the Swedish Biotechs industry average (19.1x)

Price to Sales Ratio vs Fair Ratio

What is SANION's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SANION PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SANION's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of SANION when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SANION's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SANION's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SANION's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Saniona forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Saniona has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of SANION’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Saniona competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Saniona performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SANION is currently unprofitable.

Growing Profit Margin: SANION is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SANION is unprofitable, and losses have increased over the past 5 years at a rate of 59.4% per year.

Accelerating Growth: Unable to compare SANION's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SANION is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).

Return on Equity

High ROE: SANION has a negative Return on Equity (-277.71%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Saniona's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SANION's short term assets (SEK304.1M) exceed its short term liabilities (SEK89.9M).

Long Term Liabilities: SANION's short term assets (SEK304.1M) exceed its long term liabilities (SEK92.4M).

Debt to Equity History and Analysis

Debt Level: SANION has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SANION's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SANION has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SANION has less than a year of cash runway if free cash flow continues to reduce at historical rates of 49% each year

Discover healthy companies


What is Saniona current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SANION's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SANION's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SANION's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SANION's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SANION has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Thomas Feldthus (61 yo)





Mr. Thomas Feldthus, M.Sc., MBA, served as Independent Director at Scandion Oncology A/S since 2018 until May 25, 2022. He serves as Chief Executive Officer at Saniona AB (publ) since April 30, 2022. He co...

CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: SANION's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: SANION's board of directors are considered experienced (6.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Saniona AB (publ)'s employee growth, exchange listings and data sources

Key Information

  • Name: Saniona AB (publ)
  • Ticker: SANION
  • Exchange: OM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr193.396m
  • Shares outstanding: 62.39m
  • Website:

Number of Employees


  • Saniona AB (publ)
  • Smedeland 26B
  • Glostrup
  • Capital Region of Denmark
  • 2600
  • Denmark


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.